Colchicine to Weather the Cytokine Storm in Hospitalized Patients with COVID-19
Luigi Brunetti, Oumou Diawara, Andrew Tsai, Bonnie L Firestein, Ronald G Nahass, George Poiani, Naomi Schlesinger
Journal of Clinical Medicine, doi:10.3390/jcm9092961
The repurposing of colchicine for the treatment of COVID-19 was suggested based in its immunomodulatory, anti-inflammatory, and anti-viral properties. We performed a single-center propensity score matched cohort study, including all consecutive COVID-19 patients admitted to a community hospital between 1 March 2020 and 30 May 2020. Patients were stratified according to the receipt of colchicine. The primary endpoint was defined as in-hospital death within 28-days follow-up. Secondary endpoints included favorable change in the Ordinal Scale for Clinical Improvement on days 14 and 28 versus baseline, proportion of patients not requiring supplemental oxygen on days 14 and 28, and proportion of patients discharged by day 28. In total data for 303 PCR positive COVID-19 patients were extracted and 66 patients were included in the 1:1 matched cohort study. At the end of the 28 day follow-up, patients receiving colchicine were approximately five times more likely to be discharged (odds ratio, 5.0; 95% confidence interval, 1.25-20.1; p = 0.023) and when comparing mortality, there were 3 deaths (9.1%) in patients receiving colchicine versus 11 deaths (33.3%) in the groups receiving standard of care (odds ratio, 0.20; 95% confidence interval, 0.05-0.80; p = 0.023). These observations warrant further investigation in large controlled clinical trials.
Conflicts of Interest: The authors declare no conflict of interest.
References
Bhimraj, Morgan, Shumaker, Lavergne, Baden et al., Infectious Diseases Society of America Guidelines on the Treatment and Management of Patients with COVID-19, Clin. Infect. Dis,
doi:10.1093/cid/ciaa478Cumhur Cure, Kucuk, Cure, Colchicine may not be effective in COVID-19 infection; it may even be harmful?, Clin. Rheumatol,
doi:10.1007/s10067-020-05144-xDeftereos, Giannopoulos, Vrachatis, Siasos, Giotaki et al., Effect of Colchicine vs Standard Care on Cardiac and Inflammatory Biomarkers and Clinical Outcomes in Patients Hospitalized With Coronavirus Disease 2019: The GRECCO-19 Randomized Clinical Trial, JAMA Netw. Open,
doi:10.1001/jamanetworkopen.2020.13136Della-Torre, Della-Torre, Kusanovic, Scotti, Ramirez et al., Treating COVID-19 with colchicine in community healthcare setting, Clin. Immunol,
doi:10.1016/j.clim.2020.108490Gendelman, Amital, Bragazzi, Watad, Chodick, Continuous hydroxychloroquine or colchicine therapy does not prevent infection with SARS-CoV-2: Insights from a large healthcare database analysis, Autoimmun. Rev,
doi:10.1016/j.autrev.2020.102566Group, Horby, Lim, Emberson, Mafham et al., Dexamethasone in Hospitalized Patients with Covid-19-Preliminary Report, N. Engl. J. Med,
doi:10.1056/NEJMoa2021436Jackman, Rhoads, Cornwell, Kandarian, Microtubule-mediated NF-kappaB activation in the TNF-alpha signaling pathway, Exp. Cell Res,
doi:10.1016/j.yexcr.2009.08.020Parra-Medina, Sarmiento-Monroy, Rojas-Villarraga, Garavito, Montealegre-Gomez et al., Colchicine as a possible therapeutic option in COVID-19 infection, Clin. Rheumatol,
doi:10.1007/s10067-020-05247-5Piantoni, Patroni, Toniati, Furloni, Franceschini et al., Why not to use colchicine in COVID-19? An oldanti-inflammatory drug for a novel auto-inflammatory disease, Rheumatology,
doi:10.1093/rheumatology/keaa217Richardson, Hirsch, Narasimhan, Crawford, Mcginn et al., Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area, JAMA,
doi:10.1001/jama.2020.6775Richter, Boldescu, Graf, Streicher, Dimoglo et al., Synthesis, Biological Evaluation, and Molecular Docking of Combretastatin and Colchicine Derivatives and their hCE1-Activated Prodrugs as Antiviral Agents, ChemMedChem,
doi:10.1002/cmdc.201800641Scarsi, Piantoni, Colombo, Airo, Richini et al., Association between treatment with colchicine and improved survival in a single-centre cohort of adult hospitalised patients with COVID-19 pneumonia and acute respiratory distress syndrome, Ann. Rheum. Dis,
doi:10.1136/annrheumdis-2020-217712Tardif, Kouz, Waters, Bertrand, Diaz et al., Efficacy and Safety of Low-Dose Colchicine after Myocardial Infarction, N. Engl. J. Med,
doi:10.1056/NEJMoa1912388Von Elm, Altman, Egger, Pocock, Gotzsche et al., Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: Guidelines for reporting observational studies, BMJ,
doi:10.1136/bmj.39335.541782.AD{ 'indexed': {'date-parts': [[2024, 3, 23]], 'date-time': '2024-03-23T05:20:52Z', 'timestamp': 1711171252082},
'reference-count': 23,
'publisher': 'MDPI AG',
'issue': '9',
'license': [ { 'start': { 'date-parts': [[2020, 9, 14]],
'date-time': '2020-09-14T00:00:00Z',
'timestamp': 1600041600000},
'content-version': 'unspecified',
'delay-in-days': 0,
'URL': 'https://creativecommons.org/licenses/by/4.0/'}],
'content-domain': {'domain': [], 'crossmark-restriction': False},
'abstract': '<jats:p>The repurposing of colchicine for the treatment of COVID-19 was suggested based in '
'its immunomodulatory, anti-inflammatory, and anti-viral properties. We performed a '
'single-center propensity score matched cohort study, including all consecutive COVID-19 '
'patients admitted to a community hospital between 1 March 2020 and 30 May 2020. Patients were '
'stratified according to the receipt of colchicine. The primary endpoint was defined as '
'in-hospital death within 28-days follow-up. Secondary endpoints included favorable change in '
'the Ordinal Scale for Clinical Improvement on days 14 and 28 versus baseline, proportion of '
'patients not requiring supplemental oxygen on days 14 and 28, and proportion of patients '
'discharged by day 28. In total data for 303 PCR positive COVID-19 patients were extracted and '
'66 patients were included in the 1:1 matched cohort study. At the end of the 28 day '
'follow-up, patients receiving colchicine were approximately five times more likely to be '
'discharged (odds ratio, 5.0; 95% confidence interval, 1.25–20.1; p = 0.023) and when '
'comparing mortality, there were 3 deaths (9.1%) in patients receiving colchicine versus 11 '
'deaths (33.3%) in the groups receiving standard of care (odds ratio, 0.20; 95% confidence '
'interval, 0.05–0.80; p = 0.023). These observations warrant further investigation in large '
'controlled clinical trials.</jats:p>',
'DOI': '10.3390/jcm9092961',
'type': 'journal-article',
'created': {'date-parts': [[2020, 9, 14]], 'date-time': '2020-09-14T13:04:53Z', 'timestamp': 1600088693000},
'page': '2961',
'source': 'Crossref',
'is-referenced-by-count': 58,
'title': 'Colchicine to Weather the Cytokine Storm in Hospitalized Patients with COVID-19',
'prefix': '10.3390',
'volume': '9',
'author': [ { 'ORCID': 'http://orcid.org/0000-0003-0565-6167',
'authenticated-orcid': False,
'given': 'Luigi',
'family': 'Brunetti',
'sequence': 'first',
'affiliation': []},
{'given': 'Oumou', 'family': 'Diawara', 'sequence': 'additional', 'affiliation': []},
{'given': 'Andrew', 'family': 'Tsai', 'sequence': 'additional', 'affiliation': []},
{ 'ORCID': 'http://orcid.org/0000-0002-1679-3565',
'authenticated-orcid': False,
'given': 'Bonnie L.',
'family': 'Firestein',
'sequence': 'additional',
'affiliation': []},
{'given': 'Ronald G.', 'family': 'Nahass', 'sequence': 'additional', 'affiliation': []},
{ 'ORCID': 'http://orcid.org/0000-0001-9983-0386',
'authenticated-orcid': False,
'given': 'George',
'family': 'Poiani',
'sequence': 'additional',
'affiliation': []},
{ 'ORCID': 'http://orcid.org/0000-0002-1558-1202',
'authenticated-orcid': False,
'given': 'Naomi',
'family': 'Schlesinger',
'sequence': 'additional',
'affiliation': []}],
'member': '1968',
'published-online': {'date-parts': [[2020, 9, 14]]},
'reference': [ {'key': 'ref1', 'doi-asserted-by': 'publisher', 'DOI': '10.1056/NEJMoa2021436'},
{'key': 'ref2'},
{'key': 'ref3', 'doi-asserted-by': 'publisher', 'DOI': '10.1093/cid/ciaa478'},
{'key': 'ref4'},
{'key': 'ref5', 'doi-asserted-by': 'publisher', 'DOI': '10.1161/CIRCULATIONAHA.120.047164'},
{'key': 'ref6', 'doi-asserted-by': 'publisher', 'DOI': '10.1056/NEJMoa1912388'},
{'key': 'ref7', 'doi-asserted-by': 'publisher', 'DOI': '10.1007/s40495-020-00225-6'},
{'key': 'ref8', 'doi-asserted-by': 'publisher', 'DOI': '10.1007/s00018-002-8453-3'},
{'key': 'ref9', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/j.yexcr.2009.08.020'},
{'key': 'ref10', 'doi-asserted-by': 'publisher', 'DOI': '10.1002/cmdc.201800641'},
{'key': 'ref11'},
{'key': 'ref12', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/0895-4356(92)90133-8'},
{ 'key': 'ref13',
'unstructured': 'World Health Organization (WHO) R&D Blueprint Group\n'
'https://www.who.int/blueprint/priority-diseases/key-action/COVID-19_Treatment_Trial_Design_Master_Protocol_synopsis_Final_18022020.pdf'},
{'key': 'ref14', 'doi-asserted-by': 'publisher', 'DOI': '10.1136/bmj.39335.541782.AD'},
{'key': 'ref15', 'doi-asserted-by': 'publisher', 'DOI': '10.1007/s10067-020-05144-x'},
{ 'key': 'ref16',
'doi-asserted-by': 'publisher',
'DOI': '10.1001/jamanetworkopen.2020.13136'},
{'key': 'ref17', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/j.autrev.2020.102566'},
{'key': 'ref18', 'doi-asserted-by': 'publisher', 'DOI': '10.1007/s10067-020-05247-5'},
{'key': 'ref19', 'doi-asserted-by': 'publisher', 'DOI': '10.1093/rheumatology/keaa217'},
{'key': 'ref20', 'doi-asserted-by': 'publisher', 'DOI': '10.1136/annrheumdis-2020-217712'},
{'key': 'ref21', 'doi-asserted-by': 'publisher', 'DOI': '10.1136/annrheumdis-2020-218759'},
{'key': 'ref22', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/j.clim.2020.108490'},
{'key': 'ref23', 'doi-asserted-by': 'publisher', 'DOI': '10.1001/jama.2020.6775'}],
'container-title': 'Journal of Clinical Medicine',
'original-title': [],
'language': 'en',
'link': [ { 'URL': 'https://www.mdpi.com/2077-0383/9/9/2961/pdf',
'content-type': 'unspecified',
'content-version': 'vor',
'intended-application': 'similarity-checking'}],
'deposited': { 'date-parts': [[2020, 9, 16]],
'date-time': '2020-09-16T15:12:31Z',
'timestamp': 1600269151000},
'score': 1,
'resource': {'primary': {'URL': 'https://www.mdpi.com/2077-0383/9/9/2961'}},
'subtitle': [],
'short-title': [],
'issued': {'date-parts': [[2020, 9, 14]]},
'references-count': 23,
'journal-issue': {'issue': '9', 'published-online': {'date-parts': [[2020, 9]]}},
'alternative-id': ['jcm9092961'],
'URL': 'http://dx.doi.org/10.3390/jcm9092961',
'relation': {},
'ISSN': ['2077-0383'],
'subject': ['General Medicine'],
'container-title-short': 'JCM',
'published': {'date-parts': [[2020, 9, 14]]}}
